Skip to main content
Elsevier

The Neuroscience of Parkinson's Disease

  • 1st Edition - September 23, 2020
  • Latest edition
  • Editors: Colin R. Martin, Victor R. Preedy
  • Language: English

The Neuroscience of Parkinson’s Disease (two volume set) provides a single source of material covering different scientific domains of neuropathology underlying this condit… Read more

Description

The Neuroscience of Parkinson’s Disease (two volume set) provides a single source of material covering different scientific domains of neuropathology underlying this condition. The book covers a wide range of subjects and unravels the complex relationships between genetics, molecular biology, pharmaceutical chemistry, neurobiology, imaging, assessments, and treatment regimens. The book also fills a much-needed gap as a "one-stop" synopsis of everything to do with the neurology and neuroscience related to Parkinson’s disease—from chemicals and cells to individuals. It is an invaluable resource for neuroscientists, neurologists, and anyone in the field.

Key features

  • Offers the most comprehensive coverage of a broad range of topics related to Parkinson's disease
  • Serves as a foundational collection for neuroscientists and neurologists on the biology of disease and brain dysfunction
  • Contains in each chapter an abstract, key facts, mini dictionary of terms, and summary points to aid in understanding
  • Features preclinical and clinical studies to help researchers map out key areas for research and further clinical recommendations
  • Serves as a "one-stop" source for everything you need to know about Parkinson’s disease

Readership

Neuroscientists/neurologists, psychologists, health scientists, public health workers, research scientists, pharmacologists, and physicians. Graduate/postgraduate students, lecturers, and professors

Table of contents

DIAGNOSIS AND MANAGEMENT IN PARKINSON'S DISEASE

Foreword

Virginia Bottomley

Preface

I. Introductory Chapters and Setting the Scene

1. Progression of symptoms in Parkinson's disease

Lucilla Parnetti

2. Cellular pathophysiology and basal ganglia dysfunction in Parkinson's disease: An Overview

Heinz Reichmann and Kai Felix Loewenbrueck

3. The role of environmental toxins and inflammation in Parkinson’s disease pathophysiology: a historical perspective and research-based evidence

Heinz Reichmann and Kai Felix Loewenbrueck

4. Risk factors in Parkinson's Disease: genetic and nongenetic

Evangelos Evangelou

5. Recent developments in the etiology, treatment and potential therapeutic targets for Parkinson's Disease: a focus on biochemistry

Athanasios Alexiou

6. Facial emotions and Parkinson's disease

G. Di Gennaro and Marco De Risi

7. The role of the circadian system in Parkinson’s Disease

G. Willis

8. Parkinson's disease and social media

Ibrahim S. Al-Busaidi

9. Sleep in Parkinson's disease

Marcelo M. S. Lima

10. Recurrent falls in Parkinson's disease

Lorena Rosa Santos de Almeida

11. Parkinsons patients deciding their own treatment

J. Koerts

12. Visual impairment in Parkinson's disease

Alessandro Arrigo

13. Autonomic problems in Parkinson’s disease: a focus on the bladder

Ryuji Sakakibara

14. Autonomic problems in Parkinson’s disease: a focus on the bowel

Ryuji Sakakibara

15. Linking and comparing nonmotor symptoms in ageing and Parkinson’s disease

Petra Bago Rozankovic

16. Progression of motor symptoms in Parkinson's Disease

Joana Ribeiro and Daniela Vieira

17. The stigma of Parkinson's disease

Benjamin K.P. Woo

II. Biomarkers, Instruments, Diagnosis and Assessments

18. Better neuroradiological approaches for the diagnosis of early stage Parkinson's disease patients

Tatsuro Mutoh

19. Use of positron emission tomography (PET) as a diagnostic and differential diagnostic tool in Parkinsonian syndromes

Maja Trost

20. Finger typing for the detection of early Parkinson's Disease

Warwick Adams

21. CSF biomarkers of Parkinson's disease

P. Lewitt

22. Application of eye movement tasks as an aid to understanding Parkinson's disease pathophysiology

Kikuro Fukushima

23. Measuring quality of life

Pablo Martinez Martin and Camen Rodriquez-Blazquez

24. Clinically assessing cognitive function in Parkinson’s disease

Ryan Anderton

III. Pharmacological Treatments, Other Agents and Strategies

25. Good news for the drug therapy of Parkinson`s disease

L. Bergantin

26. Dopamine Agonists and Parkinson’s disease: an overview

Aloke K. Dutta

27. Management with apomorphine in Parkinson’s disease

Manon Auffret

28. Management with MAO-B Inhibitors in Parkinson’s disease

T. Mueller

29. Management with antibiotics in Parkinson’s disease

Elaine Del-Bel and Mariza Bortolanza

30. Administration of dopamine in the brain in Parkinson’s disease

David Devos

31. Placebo and nocebo effects in Parkinson's disease

Fabrizio Benedetti

32. Levodopa-induced dyskinesias

N. S. Narayanan and Stephanie Alberico

33. Cannabinoid receptor type 2 as a therapeutic target for Parkinson’s disease

Miguel Abellanas and M. Aymerich

IV. Non-Pharmacological, Novel and Other Treatment Procedures

34. Deep Brain Stimulation Surgery in Parkinson's Disease

Hesham Abboud

35. Gene delivery for Parkinson’s disease

M. Airavaara and Andrii Domanskyi

36. Transdifferentiation of glial cells into dopamine neutrons via viral vectors/ Introducing transgenes into cells into the brain

M. Airavaara and Andrii Domanskyi

37. Urso- and tauroursodeoxycholic acids as anti-apoptotic agents: Modulation of Parkinson's disease

Noha Abdelkader

38. Interlinking potential therapy with botulinum neurotoxin A and Parkinson's disease

Andreas Wree

39. Neuropeptide CART (cocaine-amphetamine-regulated transcript) and usage in Parkinson's disease

P. Mao

40. Photobiomodulation as a neuroprotective strategy for Parkinson’s disease

Daniel M. Johnstone

41. Assisted devices in Parkinson's disease

Roongroj Bhidayasiri

　

　

GENETICS, NEUROLOGY, BEHAVIOR, AND DIET IN PARKINSON'S DISEASE

Foreword

Virginia Bottomley

Preface

I. Genetics, Molecular and Cellular Biology

1. LRRK2 genes in Parkinson’s disease: from genetics to pathobiology

Elisa Greggio and Susanna Cogo

2. Alpha-synuclein gene and Parkinson’s disease

Leonidas Stefanis

3. The DJ-1 gene and protein: links with Parkinson's Disease

Paul R. Fisher

4. Gene expression in the connection between 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP) and tyrosine hydroxylase

Gelareh Alam and Jason Richardson

5. Linking GBA variants and Parkinson's disease

Mathias Toft

6. Astrocytes and microglia in Parkinson’s disease and its animal models

Katarzyna Z. Kuter

7. Autophagy in Parkinson’s disease

Sandra Morais Cardoso and Nilza Manadas

8. Mitochondria in Parkinson’s disease

Sabrina Buettner

9. Signal transduction in Parkinson's disease

Mattia Volta

10. Oxidative stress signaling and regulated cell death in Parkinson’s disease

Marlene Jimenez-Del-Rio and Carlos Velez-Pardo

11. Subcellular-specific alpha-synuclein in Parkinson's Disease

Simon Geir Moller and Benjamin Rosen

12. MC1R in Parkinson's disease and association with melanoma risk

Susana Puig and Gemma Tell-Marti

13. Energy regulation and Parkison's disease

Kah-Leong Lim

14. Linking rotigotine, Parkinsons disease and brain BDNF

H. Kunugi

II. Neurology, Physiology and Imaging

15. The different syndromes in Parkinson’s disease: an overview

Maria Stamelou and Nikolaos Giagkou

16. Neuromolecular imaging in Parkinson’s disease

P. Broderick

17. Interlinking brain mapping and Parkinson's disease: MRI analysis, nigrosome 1 and nigrosome 4

Eung Yeop Kim

18. Interconnecting Parkinson’s disease, computed tomography (CT) and microelectrode recording in deep brain stimulation

Sepehr Sani and Ryan B. Kochanski

19. Linking diffusion tensor imaging (DTI), microstructures and Parkinson’s disease

Yu Zhang

20. Hypointensity in the substantia nigra pars compacta in Parkinson’s disease

Xiaoping Hu and Jason Langley

21. Vagal motoneurons in Parkinson’s disease

Joshua A. Goldberg and Ruth Musgrove

22. Circadian clock disruption and neuroinflammation in Parkinson’s disease: a new perspective

Elisabetta Lauretti and Domenico Pratico

23. Motor cortex stimulation in Parkinson’s disease

A. Lavano

24. Action programming disorders associated with Parkinson's Disease

Kenneth M. Heilman

25. The striatal medium spiny neurons (MSNs): what they are and how they link with Parkinson's disease

Fu-Ming Zhou

26. Disruptions of frontostriatal language functions in Parkinson's Disease

Adolfo M. Garcia

27. Synuclein and neuroinflammation in Parkinson's disease

Luigi Bubacco

28. Tau and its interactions with other proteins in neurodegenerative disease

Paul R. Fisher

29. Dopamine and the renin-angiotensin system in neuronal tissues Parkinson's Disease

Jose Luis Labandeira Garcia

30. Restoring dopamine levels in Parkinson’s disease

Henning Ulrich and Ágatha Oliveira-Giacomelli

III. Behaviour and Psychopathology

31. Motivation and motivational aspects of Parkinson's disease

Abdeslam Chagraoui

32. Linking anxiety, cognitive and sensory deficits to gait and balance in Parkinson’s disease

Quincy J. Almeida

33. Interlinking motor program of gait and bradykinesia in Parkinson's disease

Tateo Warabi

34. Olfactory features in Parkinson's disease

Marcelo M. S. Lima

IV. Diet And Nutrition

35. Interlinking dementia in Parkinson's disease: and nutritional correlates of body composition

Arthur Oscar Schelp

36. The role of the gut microbiota in Parkinson's disease

Ryan Anderton and Jade Kenna

37. Swallowing defects in Parkinson’s disease

Maira Rozenfeld Olchik

38. The Mini Nutritional Assessment (MNA ) and applications to Parkinson’s disease

Svetlana Tomic

39. Bacopa monnieri extract and Parkinson’s disease

Ravikumar Hosamani

V. Models, Modelling and Resources

40. 6-hydroxydopamine-induced model of Parkinson’s disease

Katarzyna Kaczynska

41. Knockdown transgenic Drosophila and Parkinson’s disease

Carlos Velez-Pardo and Marlene Jimenez-Del-Rio

42. Evidence for neuroprotection in animal models of Parkinson’s disease

John Mitrofanis

43. Modelling with the A53T alpha-synuclein model of Parkinson’s disease

CW Ip

44. Linking the leucine-rich repeat kinase 2 (LRRK2) gene, animals models and Parkinson’s disease

Yulan Xiong

Resources

Rajkumar Rajendram

Review quotes

"This is an outstanding addition to the literature that provides a comprehensive, contemporary, evidence-based review of Parkinson's disease. It will be a worthy inclusion for libraries of any students, researchers, and physicians involved in Parkinson's disease treatment or research."—Doody

Product details

  • Edition: 1
  • Latest edition
  • Published: December 21, 2020
  • Language: English

About the editors

CM

Colin R. Martin

Colin R. Martin RN, BSc, MSc, PhD, MBA, YCAP, FHEA, C.Psychol, AFBPsS, C.Sci is Professor of Clinical Psychobiology and Applied Psychoneuroimmunology and Clinical Director of the Institute of Health and Wellbeing at the University of Suffolk, UK. He is a Chartered Health Psychologist and a Chartered Scientist. He also trained in analytical biochemistry, this aspect reflecting the psychobiological focus of much of his research within mental health. He has published or has in press well over 300 research papers and book chapters. He is a keen book author and editor having written and/or edited more than 50 books. These outputs include the prophetic insight into the treatment of neurological disease, Handbook of Behavior, Food and Nutrition (2011), Nanomedicine and the Nervous System (2012), Oxidative Stress and Dietary Antioxidants in Neurological Disease (2020), Zika Virus Impact, Diagnosis, Control and Models (2021), Factors Affecting Neurodevelopment: Genetics, Neurology, Behavior and Diet (2021), Diagnosis and Treatment of Spinal Cord Injury (2022), The Neurobiology, Physiology, and Psychology of Pain (2022) and The Handbook of Lifespan Cognitive Behavioral Therapy: Childhood, Adolescence, Pregnancy, Adulthood, and Aging (2023). Professor Martin is particularly interested in all aspects of the relationship between underlying physiological substrates and behavior, particularly in how these relationships manifest in both acute and chronic psychiatric disorder. He has published original research germane to significant mental health disorders including the areas of schizophrenia, anxiety, depression, self-esteem, alcohol and drug dependency, high secure forensic mental health and personality disorder. He has a keen interest in the impact of postviral illness and is actively involved in clinical research post-Covid pandemic and in particular, the impact of Long Covid on psychological, neurological, physiological and social functioning. He is involved in collaborative International research with many European and Non-European countries.
Affiliations and expertise
Visiting Professor of Perinatal Wellbeing, Institute for Health and Wellbeing, University of Suffolk, Ipswich, UK

VP

Victor R. Preedy

Victor R. Preedy BSc, PhD, DSc, FRSB, FRSPH, FRSC, FRCPath graduated with an Honours Degree in Biology and Physiology with Pharmacology. After gaining his University of London PhD, he received his Membership of the Royal College of Pathologists. He was later awarded his second doctorate (DSc), for his contribution to protein metabolism in health and disease. He is Professor of Clinical Biochemistry (Hon) at King’s College Hospital and Emeritus Professor of Nutritional Biochemistry at King’s College London. He has Honorary Professorships at the University of Hull, and the University of Suffolk. Professor Preedy was the Founding Director and then long-term Director of the Genomics Centre at King’s College London from 2006 to 2020. Professor Preedy has been awarded fellowships of the Royal Society of Biology, the Royal College of Pathologists, the Royal Society for the Promotion of Health, the Royal Institute of Public Health, the Royal Society for Public Health, the Royal Society of Chemistry and the Royal Society of Medicine. He carried out research when attached to the National Heart Hospital (part of Imperial College London), The School of Pharmacy (now part of University College London) and the MRC Centre at Northwick Park Hospital. He has collaborated with international research groups in Finland, Japan, Australia, USA, and Germany. To his credit, Professor Preedy has published over 750 articles, which includes peer-reviewed manuscripts based on original research, abstracts and symposium presentations, reviews and edited books.
Affiliations and expertise
Professor, Department of Clinical Biochemistry, King’s College Hospital, London, UK; Emeritus Professor, Faculty of Life Sciences and Medicine, King’s College London, UK; Visiting Professor, University of Hull, UK